Current knowledge on diagnosis and staging of neuroendocrine tumors

Cancer and Metastasis Reviews

Volumn 30, Issue SUPPL. 1, 2011, Pages

  Öberg, Kjell ^a   Castellano, Daniel ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Biomarkers; GEP NETs; Molecular imaging; Neuroendocrine tumor; TNM staging; WHO classification

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE GA 68; 5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTAMINE C 11; 6 FLUORODOPA F 18; BIOLOGICAL MARKER; CHROMOGRANIN A; DOPAMIN F 18; FLUORODEOXYGLUCOSE F 18; GASTRIN; GLUCAGON; INSULIN; KI 67 ANTIGEN; NEURON SPECIFIC ENOLASE; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CARCINOID SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FOLLOW UP; GASTRIN BLOOD LEVEL; GLUCAGON BLOOD LEVEL; GLUCAGONOMA; HISTOPATHOLOGY; HUMAN; INSULIN BLOOD LEVEL; INSULINOMA; LIVER METASTASIS; MITOSIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIODIAGNOSIS; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR BIOPSY; VERNER MORRISON SYNDROME; ZOLLINGER ELLISON SYNDROME;

HUMANS; MOLECULAR IMAGING; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953276774     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-011-9292-1     Document Type: Article

References (31)

1. O Lubarsch 1867 Ueber den primaren Krebs des Ileum, nebst Bemerkungen über das gleichzeitige Vorkommen von Krebs und Tuberkuolose Virchow Archiv Pathol Anatom Physiol Klin Med 111 280 317 10.1007/BF01966242
2. IM Modlin K Oberg DC Chung, et al. 2008 Gastroenteropancreatic neuroendocrine tumours The Lancet Oncology 9 1 61 72 18177818 10.1016/S1470-2045(07)70410-2 1:CAS:528:DC%2BD1cXivVOltQ%3D%3D
3. IM Modlin KD Lye M Kidd 2003 A 5-decade analysis of 13,715 carcinoid tumors Cancer 97 4 934 59 12569593 10.1002/cncr.11105 (Pubitemid 36173145)
4. IM Modlin M Kidd I Latich, et al. 2005 Current status of gastrointestinal carcinoids Gastroenterology 128 6 1717 51 15887161 10.1053/j.gastro.2005.03.038 (Pubitemid 40692562)
5. K Oberg 2005 Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's) Roczniki Akademii Medycznej w Bialymstoku 50 62 8 16358941 1:STN:280:DC%2BD2MnntFagtw%3D%3D
6. JC Reubi B Waser 2003 Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting European Journal of Nuclear Medicine and Molecular Imaging 30 5 781 93 12707737 10.1007/s00259-003-1184-3 1:CAS:528:DC%2BD3sXjsF2ksbs%3D (Pubitemid 36612963)
7. R Guillemin 2005 Hypothalamic hormones a.k.a. hypothalamic releasing factors The Journal of Endocrinology 184 1 11 28 15642779 10.1677/joe.1.05883 1:CAS:528:DC%2BD2MXptVOmsw%3D%3D (Pubitemid 40207557)
8. KE Oberg JC Reubi DJ Kwekkeboom, et al. 2010 Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy Gastroenterology 139 3 742 53 20637207 10.1053/j.gastro.2010.07.002 753 e1
9. SV Welin ET Janson A Sundin, et al. 2004 High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours European Journal of Endocrinology 151 1 107 12 15248829 10.1530/eje.0.1510107 1:CAS:528:DC%2BD2cXmsFelu7o%3D (Pubitemid 39117371)
10. C Waldherr M Pless HR Maecke, et al. 2002 Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC Journal of Nuclear Medicine 43 5 610 6 11994522 1:CAS:528:DC%2BD38XktlOltbk%3D (Pubitemid 34507110)
11. K Oberg 1999 Neuroendocrine gastrointestinal tumors-a condensed overview of diagnosis and treatment Annals of Oncology 10 Suppl 2 S3 8 10399026 10.1023/A:1027336026601
12. M Stridsberg B Eriksson K Oberg, et al. 2003 A comparison between three commercial kits for chromogranin A measurements The Journal of Endocrinology 177 2 337 41 12740022 10.1677/joe.0.1770337 1:CAS:528:DC%2BD3sXktlyntbY%3D (Pubitemid 36656407)
13. B Eriksson H Arnberg K Oberg, et al. 1989 Chromogranins-new sensitive markers for neuroendocrine tumors Acta Oncológica 28 3 325 9 2545231 10.3109/02841868909111201 1:STN:280:DyaL1Mzgt1Omtg%3D%3D (Pubitemid 19166889)
14. J Leja A Essaghir M Essand, et al. 2009 Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas Modern Pathology 22 2 261 72 18953328 10.1038/modpathol.2008.174 1:CAS:528: DC%2BD1MXhtFOlsrg%3D
15. EM Duerr Y Mizukami A Ng, et al. 2008 Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis Endocr Relat Cancer 15 1 243 56 18310291 10.1677/ERC-07-0194 1:CAS:528:DC%2BD1cXkslKnu78%3D (Pubitemid 351449743)
16. G Kloppel A Perren PU Heitz 2004 The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification Annals of the New York Academy of Sciences 1014 13 27 15153416 10.1196/annals.1294.002 (Pubitemid 38594787)
17. S Ekeblad B Skogseid K Dunder, et al. 2008 Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution Clinical Cancer Research 14 23 7798 803 19047107 10.1158/1078-0432.CCR-08-0734 1:CAS:528:DC%2BD1cXhsVegtrfJ
18. G Rindi G Kloppel H Alhman, et al. 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system Virchows Archiv 449 4 395 401 16967267 10.1007/s00428-006-0250-1 1:STN:280:DC%2BD28rmtlGntA%3D%3D (Pubitemid 44451313)
19. G Rindi G Kloppel A Couvelard, et al. 2007 TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system Virchows Archiv 451 4 757 62 17674042 10.1007/s00428-007-0452-1 1:STN:280:DC%2BD2srnsVyjsw%3D%3D (Pubitemid 47497934)
20. L Fischer J Kleeff I Esposito, et al. 2008 Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas The British Journal of Surgery 95 5 627 35 18306152 10.1002/bjs.6051 1:STN:280:DC%2BD1c3ksFeqsA%3D%3D
21. UF Pape H Jann J Muller-Nordhorn, et al. 2008 Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors Cancer 113 2 256 65 18506737 10.1002/cncr.23549
22. B Eriksson K Oberg M Stridsberg 2000 Tumor markers in neuroendocrine tumors Digestion 62 Suppl 1 33 8 10940685 10.1159/000051853 1:CAS:528: DC%2BD3cXmtVaku7w%3D (Pubitemid 30665937)
23. K Oberg ET Janson B Eriksson 1999 Tumour markers in neuroendocrine tumours Italian Journal of Gastroenterology and Hepatology 31 Suppl 2 S160 2 10604122
24. J Leja B Nilsson D Yu, et al. 2010 Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability PLoS ONE 5 1 e8916 20111709 10.1371/journal.pone.0008916
25. Modlin, I. M.; Gustafsson, B. I.; & Kidd, M. (2007). Gastrointestinal carcinoid tumors. In C. W. Howden, J. Baillie, A. L. Buchman, D. C. Metz, & I. M. Modlin (Eds.), Advances in digestive disease (pp. 203-218). Bethesda: AGA Institute Press.
26. MA Anderson S Carpenter NW Thompson, et al. 2000 Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas The American Journal of Gastroenterology 95 9 2271 7 11007228 10.1111/j.1572-0241.2000.02480.x 1:STN:280:DC%2BD3cvltFGnsg%3D%3D
27. F Gibril JC Reynolds JL Doppman, et al. 1996 Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study Annals of Internal Medicine 125 1 26 34 8644985 1:STN:280:DyaK283ksFSkug%3D%3D
28. S Adams R Baum T Rink, et al. 1998 Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours European Journal of Nuclear Medicine 25 1 79 83 9396878 1:CAS:528:DyaK2sXnvVGru7o%3D (Pubitemid 28107907)
29. KP Koopmans EG de Vries IP Kema, et al. 2006 Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study The Lancet Oncology 7 9 728 34 16945767 10.1016/S1470-2045(06)70801-4 1:CAS:528: DC%2BD28Xptlyrsr4%3D (Pubitemid 44283659)
30. H Orlefors A Sundin U Garske, et al. 2005 Whole-body (11)C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography The Journal of Clinical Endocrinology and Metabolism 90 6 3392 400 15755858 10.1210/jc.2004-1938 1:CAS:528:DC%2BD2MXkvFCltrc%3D (Pubitemid 41014303)
31. S Koukouraki LG Strauss V Georgoulias, et al. 2006 Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy European Journal of Nuclear Medicine and Molecular Imaging 33 4 460 6 16437218 10.1007/s00259-005-0006-1 1:CAS:528:DC%2BD28XjsFalurY%3D